Kaitlyn Bader, Editor

Patients can achieve reduced excessive underarm sweating after one in-office treatment.

Merck and Eisai discontinued the trial based on recommendations of an independent data monitoring committee.

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.

This week's edition of the Mainstream Patient features stories about filler fatigue in 2023, the difference between RF microneedling and traditional microneedling, IPL hair removal devices, and more.

ICYMI, this week we had stories about the role of dermatology advanced practice providers in a clinic, denovoSkin for severe burns, spesolimab receiving a permanent J-code, and more.

Investigators examined the association between fatty liver and AA subtypes.

Cutiss AG hopes to provide a safe and effective skin substitute for patients needing a skin graft after a severe burn.

Dermatology advanced practice providers work alongside physicians to improve patient care and access.

Physicians across the US saw an uptick in cosmetic procedures after workers returned to offices.

From acne and psoriasis to skin cancer and hair loss, leaders in the industry share their quick tips that help save time.

This week's edition of the Mainstream Patient features stories about inclusivity in plastic surgery, the powerful benefits of glycerin, the best mineral sunscreens according to dermatologists, and more.

ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of March.

Three major NDAs and sBLAs were accepted by the FDA in Q1 of 2023, with PDUFA dates set in 2023 and 2024.

Learning how to prescribe biologics, talking to mentors, reviewing journals, and getting involved in clinical trials are all ways to boost your expertise.

Late-breaking positive phase 2a results were presented at AAD 2023.

ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.

The UK and Netherlands study assessed tumor response rates among 91 patients.

Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.

Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

An AAD 2023 poster presentation reviewed the long-term safety periods of the TruE-AD1 and TRuE-AD2 trials.

A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA.

Bhatia shares key pearls from his sessions at AAD 2023 discussing office politics and how to run a clinical research unit.

According to his AAD 2023 session, Matarasso stresses it’s crucial to consider the type of patient you want as a loyal patient.

Dermavant’s ADORING 2 phase 3 trial met all primary and secondary endpoints.